Pediatric vaccines on the horizon

American Journal of the Medical Sciences

Volumn 340, Issue 3, 2010, Pages 226-231

  Chávez Bueno, Susana ^a   Stull, Terrence L ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Children; Pediatrics; Vaccine trials; Vaccines

Indexed keywords

ADJUVANT; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; DECAVAC; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; DT; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A HEPATITIS B VACCINE; INFLUENZA VACCINE; KINRIX; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PEDIATRIX; PENICILLIN G; PENTACEL; PHOSPHORYL LIPID A; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

CELLULAR IMMUNITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONFERENCE PAPER; DISEASE SURVEILLANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; FINANCE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INVASIVE PNEUMOCOCCAL DISEASE; MALARIA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PATHOGENESIS; PEDIATRICS; PNEUMOCOCCAL INFECTION; PRIMARY PREVENTION; RISK FACTOR; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; CHILD; FEMALE; MALE;

CHILD; FEMALE; HUMANS; MALE; PEDIATRICS; VACCINES;

EID: 77956883170     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181e939eb     Document Type: Conference Paper

References (84)

1. Centers for Disease Control and Prevention. Impact of vaccines universally recommended for children-United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999;48:243-248
2. Mackroth MS, Irwin K, Vandelaer J, et al. Immunizing school-age children and adolescents: Experience from low- and middle-income countries. Vaccine 2010;28:1138-1147
3. Murphy TV, Slade BA, Broder KR, et al; Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1-51.
4. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 2008;47:989-996
5. Musher DM. Pneumococcal vaccine-direct and indirect ("herd") effects. N Engl J Med 2006;354:1522-1524
6. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005;23:1540-1548
7. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years-United States, 2010. MMWR 2010;58:1-4.
8. National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention. Use of influenza A (H1N1) 2009 monovalent vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58:1-8.
9. Fiore AE, Shay DK, Broder K, et al; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58:1-52.
10. Markowitz LE, Dunne EF, Saraiya M, et al; Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24.
11. Committee on Infectious Diseases. Policy statement-recommended childhood and adolescent immunization schedules-United States, 2010. Pediatrics 2010;125:195-196
12. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19-35 months- United States, 2008. MMWR Morb Mortal Wkly Rep 2009;58:921-926
13. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years- United States, 2008. MMWR Morb Mortal Wkly Rep 2009;58:997-1001.
14. Hall-Baker P, Nieves E, Jajosky R, et al. Summary of notifiable diseases-United States, 2007. MMWR Morb Mortal Wkly Rep 2009; 56:1-94.
15. O'Brien KL, Wolfson LJ, Watt JP, et al; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet 2009;374:893-902.
16. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999;18:757-763
17. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-195
18. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008;8:785-795
19. Pinner RW, Rebmann CA, Schuchat A, et al. Disease surveillance and the academic, clinical, and public health communities. Emerg Infect Dis 2003;9:781-787
20. Kyaw MH, Lynfield R, Schaffner W, et al; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-1463
21. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006;295:1668-1674
22. Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41.
23. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28(4 suppl):S66-76.
24. Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J 2009;28(4 suppl): S109-18.
25. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: A randomised double-blind efficacy study. Lancet 2006;367:740-748
26. Prymula R, Kriz P, Kaliskova E, et al. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine 2009;28:71-78
27. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007;25: 6164-6166
28. Scott D, Ruckle J, Dar M, et al. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int 2008;50:295-299
29. Bryant K, Gurtman A, Girgenti D, et al. Antibody Responses to Routine Pediatric Vaccines When Administered with 13-Valent Pneumococcal Conjugate Vaccine. 47th Annual Meeting of the Infectious Diseases Society of America. Presentation Abstract 1195. Philadelphia, PA, USA; 2009.
30. Hausdorff WP, Dagan R, Beckers F, et al. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 2009;27:7257-7269
31. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: Implications for prevention of meningococcal disease. Clin Infect Dis 2010;50:184-191
32. Kumar A, Murray DL, Havlichek DH. Immunizations for the college student: A campus perspective of an outbreak and national and international considerations. Pediatr Clin North Am 2005;52:229-241
33. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005;24:57-62.
34. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005;159:907-913
35. Rennels M, King J Jr, Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004;23:429-435
36. Jackson LA, Baxter R, Reisinger K, et al; V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009;49:e1-10.
37. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: A randomized controlled trial. JAMA 2008;299:173-184
38. Perrett KP, Snape MD, Ford KJ, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 2009;28:186-193
39. Nolan T, Lambert S, Roberton D, et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine 2007;25:8487-8499
40. Marchant CD, Miller JM, Marshall GS, et al; HibMenCY-TT 005 Study Group. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010;29:48-52.
41. Marshall GS, Marchant CD, Blatter M, et al. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (hibmency) at 12 to 15 months of age. Pediatr Infect Dis J 2010;29:469-471
42. Ostergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009;27:161-168
43. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010;28:744-753
44. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009;27(suppl 2):B3-12.
45. Galloway Y, Stehr-Green P, McNicholas A, et al. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009;38:413-418
46. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001;19:2688-2691
47. Feavers IM, Pizza M. Meningococcal protein antigens and vaccines. Vaccine 2009;27(suppl 2):B42-50.
48. Snape MD, Dawson T, Morant A, et al. Immunogenicity and reactogenicity of a novel serogroup B Neisseria meningitidis vaccine administered from 6 months of age. Presented at: 16th International Pathogenic Neisseria Conference, Rotterdam, The Netherlands; 2008. Oral Presentation Abstract 069.
49. Pelton SI. Conjugate meningococcal vaccines: Lifesaving or inefficient use or both-no easy answer. Clin Infect Dis 2010;50:192-193
50. Plotkin SA. Six revolutions in vaccinology. Pediatr Infect Dis J 2005;24:1-9.
51. Plotkin SA. Vaccines: The fourth century. Clin Vaccine Immunol 2009;16:1709-1719
52. Palese P. Making better influenza virus vaccines? Emerg Infect Dis 2006;12:61-65
53. Dennehy PH. Rotavirus vaccines: An overview. Clin Microbiol Rev 2008;21:198-208.
54. Haller AA, Miller T, Mitiku M, et al. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 2000;74:11626-11635
55. Tang RS, Schickli JH, MacPhail M, et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3 proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 2003;77:10819-10828
56. Gomez M, Mufson MA, Dubovsky F, et al. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J 2009;28:655-658
57. Schleiss MR. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection. J Pediatr 2007;151:564-570
58. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: The human immunodeficiency virus (HIV). Vaccine 2006;24:4062-4081
59. Serruto D, Serino L, Masignani V, et al. Genome-based approaches to develop vaccines against bacterial pathogens. Vaccine 2009;27: 3245-3250
60. Tettelin H, Masignani V, Cieslewicz MJ, et al. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: Implications for the microbial "pan-genome". Proc Natl Acad Sci U S A 2005;102: 13950-13955
61. Maione D, Margarit I, Rinaudo CD, et al. Identification of a universal group B streptococcus vaccine by multiple genome screen. Science 2005;309:148-150
62. Lauer P, Rinaudo CD, Soriani M, et al. Genome analysis reveals pili in group B Streptococcus. Science 2005;309:105.
63. Margarit I, Rinaudo CD, Galeotti CL, et al. Preventing bacterial infections with pilus-based vaccines: The group B streptococcus paradigm. J Infect Dis 2009;199:108-115
64. Hogg JS, Hu FZ, Janto B, et al. Characterization and modeling of the Haemophilus influenzae core and supragenomes based on the complete genomic sequences of Rd and 12 clinical nontypeable strains. Genome Biol 2007;8:R103.
65. Hiller NL, Janto B, Hogg JS, et al. Comparative genomic analyses of seventeen Streptococcus pneumoniae strains: Insights into the pneumococcal supragenome. J Bacteriol 2007;189:8186-8195
66. Rinaudo CD, Telford JL, Rappuoli R, et al. Vaccinology in the genome era. J Clin Invest 2009;119:2515-2525
67. Plotkin SA. Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis 2008;47:401-409
68. Reed SG, Bertholet S, Coler RN, et al. New horizons in adjuvants for vaccine development. Trends Immunol 2009;30:23-32.
69. Schultze V, D'Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine 2008;26:3209-3222
70. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-2435
71. Lell B, Agnandji S, von Glasenapp I, et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One 2009;4:e7611.
72. Pichichero ME. New combination vaccines. Pediatr Clin North Am 2000;47:407-426
73. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 2009;183:6883-6892
74. Jambo KC, Sepako E, Heyderman RS, et al. Potential role for mucosally active vaccines against pneumococcal pneumonia. Trends Microbiol 2010;18:81-89
75. Steer AC, Batzloff MR, Mulholland K, et al. Group A streptococcal vaccines: Facts versus fantasy. Curr Opin Infect Dis 2009;22:544-552
76. Olive C, Clair T, Yarwood P, et al. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 2002;20:2816-2825
77. Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study. Vaccine 2009;27:7304-7312
78. Kim YC, Quan FS, Yoo DG, et al. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010;201:190-198
79. Glenn GM, Thomas DN, Poffenberger KL, et al. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. Vaccine 2009;27(suppl 6):G60-6.
80. Davis MM, Butchart AT, Coleman MS, et al. The expanding vaccine development pipeline, 1995-2008. Vaccine 2010;28:1353-1356
81. Offit PA. Why are pharmaceutical companies gradually abandoning vaccines? Health Aff (Millwood) 2005;24:622-630
82. Lee BY, Burke DS. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 2010;28:2806-2809
83. Freed GL, Cowan AE, Gregory S, et al. Variation in provider vaccine purchase prices and payer reimbursement. Pediatrics 2008; 122:1325-1331
84. National Vaccine Advisory Committee. Financing vaccination of children and adolescents: National Vaccine Advisory Committee recommendations. Pediatrics 2009;124(suppl 5):S558-62.